A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)

Merck Sharp & Dohme LLC143 enrolled

Overview

The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.

Study Type

OBSERVATIONAL

Enrollment

143

Conditions

Diabetes Mellitus, Type 2

Interventions

Sitagliptin Phosphate/Metformin HCl (JANUMET®)DRUG

Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Must be taking sitagliptin phosphate/metformin HCl (JANUMET®) for the treatment of type 2 diabetes mellitus * Treating physician must agree to provide information regarding the participant's treatment

Outcomes

Primary Outcomes

Number of Participants With an Adverse Event

Time frame: Up to approximately 28 months

Age of Participants Prescribed Sitagliptin Phosphate/Metformin HCl

Time frame: Up to approximately 28 months

Number of Participants With Concomitant Conditions

Time frame: Up to approximately 28 months

Number of Participants Taking Concomitant Medications

Time frame: Up to approximately 28 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.